Psoriatic Arthritis Treatment Market - By Drug Type (NSAIDs, DMARDs [Synthetic, Biologics], Biological Agents [TNF, IL-17, IL-23]), Route of Administration, Medication Type, Age Group, Distribution Channel – Global Forecast (2024 – 2032)

Psoriatic Arthritis Treatment Market - By Drug Type (NSAIDs, DMARDs [Synthetic, Biologics], Biological Agents [TNF, IL-17, IL-23]), Route of Administration, Medication Type, Age Group, Distribution Channel – Global Forecast (2024 – 2032)

Psoriatic Arthritis Treatment Market Size

Psoriatic Arthritis Treatment Market size was valued at USD 10.2 billion in 2023 and is estimated to grow at 9.7% CAGR from 2024 to 2032. The market has seen considerable growth due to the increasing prevalence of psoriatic arthritis globally.

To get key market trends

  Download Free Sample

According to data reported by the National Psoriasis Foundation, around 125 million people worldwide (2 to 3 percent of the total population) have psoriasis, and an estimated 30 percent of these individuals develop psoriatic arthritis. This significant patient population tends to drive the demand for advanced treatment options, thereby boosting market growth. Furthermore, advancements in biologic drugs and personalized medicine, alongside growing awareness about early diagnosis and treatment are significantly contributing to market expansion.
 

What are the growth opportunities in this market?

 Download Free Sample

Psoriatic arthritis treatment involves medical interventions aimed at managing the symptoms and progression of psoriatic arthritis, a chronic inflammatory disease affecting joints and skin. Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic agents targeting specific immune pathways, and corticosteroids to reduce inflammation.

Psoriatic Arthritis Treatment Market Trends

Increased investments in research and development (R&D) have led to the discovery of innovative therapies and advanced treatment options. These efforts have also facilitated the advancement in biological agents and precision medicine approaches, addressing the diverse needs of patients with psoriatic arthritis is driving the market expansion.

• For instance, in March 2024, Acelyrin, Inc. revealed promising outcomes from its global phase 2b/3 clinical trial of izokibep, a potential breakthrough in treating psoriatic arthritis. Izokibep, a small protein therapeutic targeting IL-17A presented remarkable potency, strong tissue penetration capabilities, and an extended half-life. Thus, availability of strong product pipeline and associated treatment for broader applications will spur the market growth.

Moreover, the growing aging population living with psoriasis, enhanced diagnostic technologies, government policies fostering healthcare and strategic expansions by major players further propel the market demand.

Psoriatic Arthritis Treatment Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on the drug type, the market is categorized as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biological agents, and other drug types. The biological agents segment is set to lead the market, accounting for the largest revenue of USD 3.6 billion, anticipating its dominance throughout the forecast period with a CAGR of 9.6%.

• The biological agents segment is further categorized into TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors. TNF inhibitors have emerged as the dominant segment among biological agents. These drugs inhibit the action of tumor necrosis factor-alpha, a key cytokine involved in the inflammatory process of psoriatic arthritis.
• For instance, according to a study published in Rheumatology and Therapy, biological agents were discovered to be more effective than methotrexate in preventing psoriatic arthritis among patients with psoriasis. Therefore, TNF inhibitors have demonstrated significant efficacy in reducing joint inflammation and slowing disease progression, making them the preferred choice for many patients and healthcare providers, thus dominating the biological agents segment of the market

Learn more about the key segments shaping this market

 Download Free Sample

Based on route of administration, the psoriatic arthritis treatment market is classified into topical, oral, and injectable. The injectable segment holds the largest market share of 57.7% in 2023 and is expected to maintain dominance throughout the analysis period.

• Injectable medications including biologics and traditional DMARDs offer several advantages such as precise dosing, direct delivery into the bloodstream, and convenience for patients. Also, the efficacy and safety of injectable treatments have been well-established through extensive clinical research.
• Thus, the dominance reflected the preference for efficient and effective treatment options among healthcare providers and patients managing psoriatic arthritis, thereby driving its prominence in the market.

Based on medication type, the psoriatic arthritis treatment market is segmented into branded and generics. The branded segment is expected to lead the market projecting a growth rate of 9.5% during the analysis period.

• The branded medications often developed by pharmaceutical giants offer innovative formulations and targeted approaches to managing the complex symptoms of psoriatic arthritis. With extensive R&D investments and strong brand recognition, these drugs command a significant market share. Their proven efficacy, coupled with favorable reimbursement policies, further solidified their dominance, making them the preferred choice.
• Further, generic drugs demonstrated a prominent growth rate throughout the analysis period attributed to various factors such as patent expirations of branded medications, escalating demand for economical treatment alternatives, and regulatory efforts encouraging the utilization of generics. These dynamics collectively contributed to the substantial expansion of the generic drug segment in the market.

Based on the age group, the psoriatic arthritis treatment market is segmented into below 18 years, 19-40, 41-60, and 60 above. The 41-60 age group segment is projected to reach USD 11.2 billion by 2032.

• The segment growth is due to the growing awareness of psoriatic arthritis in geriatric population base has shifted the focus of pharmaceutical companies toward developing effective treatments for this demographic. This growing concern underscored the importance of addressing the unique needs of patients, thereby driving increased investment and innovation in psoriatic arthritis treatment options.

Based on the distribution channel, the psoriatic arthritis treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market with the highest share in 2023.

• Hospital pharmacies offer a wide range of medications including biologics and disease-modifying drugs, essential for managing psoriatic arthritis.
• Also, the presence of trained healthcare professionals ensures proper administration and monitoring of these treatments, making hospital pharmacies the preferred choice for many patients seeking comprehensive care for their condition. Such aforementioned factor is expected to spur the segmental growth.

Looking for region specific data?

 Download Free Sample

The U.S. dominated the North American psoriatic arthritis treatment market accounting for USD 3.9 billion in 2023 and is anticipated to show considerable growth over the analysis period.

• U.S. holds prominence in the market due to several factors such as advanced healthcare infrastructure, widespread access to innovative treatments, and a large patient population. For instance, according to the National Psoriasis Foundation, approximately 2.4 million individuals in the U.S. are affected by psoriatic arthritis. Similarly, an estimated 15% of individuals with psoriasis may be undiagnosed with psoriatic arthritis. This high prevalence underscores the significant demand for effective treatment options, thereby driving the expansion of the market for psoriatic arthritis treatments in the U.S. market.
• Additionally, the presence of key pharmaceutical companies and research institutions coupled with supportive government policies as well as insurance coverage contribute to the market's growth.

Germany exhibited a high growth potential in the European psoriatic arthritis treatment market.

• Germany boasts one of the largest economies in Europe with robust healthcare infrastructure and advanced medical research facilities. This enables the country to offer cutting-edge treatments and therapies for psoriatic arthritis.
• Also, Germany has a high prevalence of psoriatic arthritis cases, which drives demand for effective treatments and encourages pharmaceutical companies to invest in research and development.
• Moreover, the country's well-established health insurance system ensures widespread access to treatments, further solidifying its prominence in the European psoriatic arthritis treatments market.

The Asia Pacific psoriatic arthritis treatment market is poised for rapid growth with a CAGR of 10.2% during the forecast period.

• The Asia Pacific market is poised for rapid growth due to several factors such as the region's expanding population, product approvals coupled with increasing awareness and diagnosis rates of psoriatic arthritis.
• For instance, in December 2023, UCB received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for BIMZELX, expanding its indication for the treatment of adults with psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis. This regulatory approval bolstered the company's capability in advancing psoriasis treatment options and also for related conditions including psoriatic arthritis, marking significant progress in addressing these challenging diseases.
• Thus, the introduction of innovative treatment options and strategic investments by pharmaceutical companies in the region are expected to fuel market growth.

Psoriatic Arthritis Treatment Market Share

The competitive landscape of the market is characterized by intense competition, with companies focusing on research and development to introduce novel treatments and gain a competitive edge. Several key players offer a range of treatment options, including biologics, DMARDs, and corticosteroids. Also, strategic collaborations, mergers, and acquisitions are common strategies employed by players to strengthen their market position and expand their product portfolios in the rapidly evolving landscape of psoriatic arthritis treatment.

Psoriatic Arthritis Treatment Market Companies

Few of the prominent players operating in the psoriatic arthritis treatment industry include

• Abbvie Inc.
• Amgen Inc.
• Biogen
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Fujifilm Kyowa Kirin Biologics Co., Ltd.
• Janssen Pharmaceutical Companies (Johnson and Johnson)
• Merck KGA
• Novartis AG
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.
• Sanofi
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd. 
• UCB S.A

Psoriatic Arthritis Treatment Industry News

• In April 2024, Alvotech and Teva Pharmaceuticals' biosimilar, Selarsdi, gained FDA approval as an alternative to Stelara. Indicated for patients aged 6 and above with moderate to severe plaque psoriasis and active psoriatic arthritis. This approval bolstered the biosimilar development and enhanced the psoriatic arthritis treatment.
• In October 2023, Novartis received the U.S. FDA approval for an intravenous formulation of Cosentyx, extending its indication to treat adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. This approval aimed to broaden the treatment availability, complementing existing biologic intravenous therapies for psoriatic arthritis conditions.

The psoriatic arthritis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments

Click here to Buy Section of this Report

Market, By Drug Type

• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Disease-modifying antirheumatic drugs (DMARDs)
• Biological agents
  • TNF inhibitors
  • IL-17 inhibitors
  • IL-12/23 inhibitors
• Other drug types

Market, By Route of Administration

• Topical
• Oral
• Injectable

Market, By Medication Type

• Branded
• Generics

Market, By Age Group

• below 18 years
• 19-40
• 41-60
• 61 above

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa